Serveur d'exploration sur le lymphœdème

Attention, ce site est en cours de développement !
Attention, site généré par des moyens informatiques à partir de corpus bruts.
Les informations ne sont donc pas validées.

Evaluating the efficacy of rBmHATαc as a multivalent vaccine against lymphatic filariasis in experimental animals and optimizing the adjuvant formulation

Identifieur interne : 002347 ( Pmc/Checkpoint ); précédent : 002346; suivant : 002348

Evaluating the efficacy of rBmHATαc as a multivalent vaccine against lymphatic filariasis in experimental animals and optimizing the adjuvant formulation

Auteurs : Gajalakshmi Dakshinamoorthy ; Ramaswamy Kalyanasundaram

Source :

RBID : PMC:3866973

Abstract

Developing an effective vaccine against lymphatic filariasis will complement the WHO's effort to eradicate the infection from endemic areas. Currently 83 different countries are endemic for this infection and over 1 billion people are at risk. An effective vaccine coupled with mass drug administration will reduce the morbidity and social stigma associated with this gruesome disease. Several potential vaccine candidates that can confer partial protection in experimental animals have been reported from different laboratories. However, no licensed vaccines are currently available for this disease. Among the several vaccine antigens identified from our laboratory, three most promising antigens; rBmHSPαc (α crystalline domain and c-terminal extension of Heat Shock Protein 12.6), rBmALT-2 (Abundant larval transcript) and rBmTSP LEL (Tetraspanin large extracellular loop) was further developed as a recombinant fusion protein vaccine (rBmHATαc). In a mouse model this fusion protein vaccine gave close to 68% protection following a challenge infection. To improve the vaccine efficiency of rBmHATαc, in this study we evaluated various preparations of alum (AL007, AL019, Alhydrogel and Imject® Alum) as adjuvants. Our results show that mice immunized with rBmHATαc formulated in AL007 (alum from IDRI) and/or AL019 (alum plus TLR-4 agonist from IDRI) gave the highest IgG antibody titer compared to other groups. Subsequent in vivo challenge experiments confirmed that >95% protection can be achieved when AL007 or AL019 was used as the adjuvant. However, when Imject® Alum or alhydrogel was used as the adjuvant only 76% and 72% protection respectively could be achieved. These results show that AL007 or AL019 (IDRI) is an excellent choice of adjuvant for the rBmHATαc vaccine against B. malayi L3 in mice.


Url:
DOI: 10.1016/j.vaccine.2013.10.083
PubMed: 24211167
PubMed Central: 3866973


Affiliations:


Links toward previous steps (curation, corpus...)


Links to Exploration step

PMC:3866973

Le document en format XML

<record>
<TEI>
<teiHeader>
<fileDesc>
<titleStmt>
<title xml:lang="en">Evaluating the efficacy of r
<italic>Bm</italic>
HATαc as a multivalent vaccine against lymphatic filariasis in experimental animals and optimizing the adjuvant formulation</title>
<author>
<name sortKey="Dakshinamoorthy, Gajalakshmi" sort="Dakshinamoorthy, Gajalakshmi" uniqKey="Dakshinamoorthy G" first="Gajalakshmi" last="Dakshinamoorthy">Gajalakshmi Dakshinamoorthy</name>
</author>
<author>
<name sortKey="Kalyanasundaram, Ramaswamy" sort="Kalyanasundaram, Ramaswamy" uniqKey="Kalyanasundaram R" first="Ramaswamy" last="Kalyanasundaram">Ramaswamy Kalyanasundaram</name>
</author>
</titleStmt>
<publicationStmt>
<idno type="wicri:source">PMC</idno>
<idno type="pmid">24211167</idno>
<idno type="pmc">3866973</idno>
<idno type="url">http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3866973</idno>
<idno type="RBID">PMC:3866973</idno>
<idno type="doi">10.1016/j.vaccine.2013.10.083</idno>
<date when="2013">2013</date>
<idno type="wicri:Area/Pmc/Corpus">003798</idno>
<idno type="wicri:explorRef" wicri:stream="Pmc" wicri:step="Corpus" wicri:corpus="PMC">003798</idno>
<idno type="wicri:Area/Pmc/Curation">003797</idno>
<idno type="wicri:explorRef" wicri:stream="Pmc" wicri:step="Curation">003797</idno>
<idno type="wicri:Area/Pmc/Checkpoint">002347</idno>
<idno type="wicri:explorRef" wicri:stream="Pmc" wicri:step="Checkpoint">002347</idno>
</publicationStmt>
<sourceDesc>
<biblStruct>
<analytic>
<title xml:lang="en" level="a" type="main">Evaluating the efficacy of r
<italic>Bm</italic>
HATαc as a multivalent vaccine against lymphatic filariasis in experimental animals and optimizing the adjuvant formulation</title>
<author>
<name sortKey="Dakshinamoorthy, Gajalakshmi" sort="Dakshinamoorthy, Gajalakshmi" uniqKey="Dakshinamoorthy G" first="Gajalakshmi" last="Dakshinamoorthy">Gajalakshmi Dakshinamoorthy</name>
</author>
<author>
<name sortKey="Kalyanasundaram, Ramaswamy" sort="Kalyanasundaram, Ramaswamy" uniqKey="Kalyanasundaram R" first="Ramaswamy" last="Kalyanasundaram">Ramaswamy Kalyanasundaram</name>
</author>
</analytic>
<series>
<title level="j">Vaccine</title>
<idno type="ISSN">0264-410X</idno>
<idno type="eISSN">1873-2518</idno>
<imprint>
<date when="2013">2013</date>
</imprint>
</series>
</biblStruct>
</sourceDesc>
</fileDesc>
<profileDesc>
<textClass></textClass>
</profileDesc>
</teiHeader>
<front>
<div type="abstract" xml:lang="en">
<p id="P1">Developing an effective vaccine against lymphatic filariasis will complement the WHO's effort to eradicate the infection from endemic areas. Currently 83 different countries are endemic for this infection and over 1 billion people are at risk. An effective vaccine coupled with mass drug administration will reduce the morbidity and social stigma associated with this gruesome disease. Several potential vaccine candidates that can confer partial protection in experimental animals have been reported from different laboratories. However, no licensed vaccines are currently available for this disease. Among the several vaccine antigens identified from our laboratory, three most promising antigens; r
<italic>Bm</italic>
HSPαc (α crystalline domain and c-terminal extension of Heat Shock Protein 12.6), r
<italic>Bm</italic>
ALT-2 (Abundant larval transcript) and r
<italic>Bm</italic>
TSP LEL (Tetraspanin large extracellular loop) was further developed as a recombinant fusion protein vaccine (r
<italic>Bm</italic>
HATαc). In a mouse model this fusion protein vaccine gave close to 68% protection following a challenge infection. To improve the vaccine efficiency of r
<italic>Bm</italic>
HATαc, in this study we evaluated various preparations of alum (AL007, AL019, Alhydrogel and Imject® Alum) as adjuvants. Our results show that mice immunized with r
<italic>Bm</italic>
HATαc formulated in AL007 (alum from IDRI) and/or AL019 (alum plus TLR-4 agonist from IDRI) gave the highest IgG antibody titer compared to other groups. Subsequent
<italic>in vivo</italic>
challenge experiments confirmed that >95% protection can be achieved when AL007 or AL019 was used as the adjuvant. However, when Imject® Alum or alhydrogel was used as the adjuvant only 76% and 72% protection respectively could be achieved. These results show that AL007 or AL019 (IDRI) is an excellent choice of adjuvant for the r
<italic>Bm</italic>
HATαc vaccine against
<italic>B. malayi</italic>
L3 in mice.</p>
</div>
</front>
</TEI>
<pmc article-type="research-article">
<pmc-comment>The publisher of this article does not allow downloading of the full text in XML form.</pmc-comment>
<pmc-dir>properties manuscript</pmc-dir>
<front>
<journal-meta>
<journal-id journal-id-type="nlm-journal-id">8406899</journal-id>
<journal-id journal-id-type="pubmed-jr-id">7945</journal-id>
<journal-id journal-id-type="nlm-ta">Vaccine</journal-id>
<journal-id journal-id-type="iso-abbrev">Vaccine</journal-id>
<journal-title-group>
<journal-title>Vaccine</journal-title>
</journal-title-group>
<issn pub-type="ppub">0264-410X</issn>
<issn pub-type="epub">1873-2518</issn>
</journal-meta>
<article-meta>
<article-id pub-id-type="pmid">24211167</article-id>
<article-id pub-id-type="pmc">3866973</article-id>
<article-id pub-id-type="doi">10.1016/j.vaccine.2013.10.083</article-id>
<article-id pub-id-type="manuscript">NIHMS537279</article-id>
<article-categories>
<subj-group subj-group-type="heading">
<subject>Article</subject>
</subj-group>
</article-categories>
<title-group>
<article-title>Evaluating the efficacy of r
<italic>Bm</italic>
HATαc as a multivalent vaccine against lymphatic filariasis in experimental animals and optimizing the adjuvant formulation</article-title>
</title-group>
<contrib-group>
<contrib contrib-type="author">
<name>
<surname>Dakshinamoorthy</surname>
<given-names>Gajalakshmi</given-names>
</name>
</contrib>
<contrib contrib-type="author">
<name>
<surname>Kalyanasundaram</surname>
<given-names>Ramaswamy</given-names>
</name>
</contrib>
<aff id="A1">Department of Biomedical Sciences, University of Illinois College of Medicine, Rockford, IL-61107</aff>
</contrib-group>
<author-notes>
<corresp id="CR1">
<bold>Address for correspondence and reprint requests</bold>
to Dr. K. Ramaswamy, Department of Biomedical Sciences, 1601 Parkview Avenue, College of Medicine, University of Illinois, Rockford, IL- 61107.
<email>ramswamy@uic.edu</email>
, Phone: (815) 395-5696, Fax: (815) 395-5684.</corresp>
</author-notes>
<pub-date pub-type="nihms-submitted">
<day>11</day>
<month>12</month>
<year>2013</year>
</pub-date>
<pub-date pub-type="epub">
<day>06</day>
<month>11</month>
<year>2013</year>
</pub-date>
<pub-date pub-type="ppub">
<day>17</day>
<month>12</month>
<year>2013</year>
</pub-date>
<pub-date pub-type="pmc-release">
<day>17</day>
<month>12</month>
<year>2014</year>
</pub-date>
<volume>32</volume>
<issue>1</issue>
<elocation-id>10.1016/j.vaccine.2013.10.083</elocation-id>
<permissions>
<copyright-statement>© 2013 Elsevier Ltd. All rights reserved.</copyright-statement>
<copyright-year>2013</copyright-year>
</permissions>
<abstract>
<p id="P1">Developing an effective vaccine against lymphatic filariasis will complement the WHO's effort to eradicate the infection from endemic areas. Currently 83 different countries are endemic for this infection and over 1 billion people are at risk. An effective vaccine coupled with mass drug administration will reduce the morbidity and social stigma associated with this gruesome disease. Several potential vaccine candidates that can confer partial protection in experimental animals have been reported from different laboratories. However, no licensed vaccines are currently available for this disease. Among the several vaccine antigens identified from our laboratory, three most promising antigens; r
<italic>Bm</italic>
HSPαc (α crystalline domain and c-terminal extension of Heat Shock Protein 12.6), r
<italic>Bm</italic>
ALT-2 (Abundant larval transcript) and r
<italic>Bm</italic>
TSP LEL (Tetraspanin large extracellular loop) was further developed as a recombinant fusion protein vaccine (r
<italic>Bm</italic>
HATαc). In a mouse model this fusion protein vaccine gave close to 68% protection following a challenge infection. To improve the vaccine efficiency of r
<italic>Bm</italic>
HATαc, in this study we evaluated various preparations of alum (AL007, AL019, Alhydrogel and Imject® Alum) as adjuvants. Our results show that mice immunized with r
<italic>Bm</italic>
HATαc formulated in AL007 (alum from IDRI) and/or AL019 (alum plus TLR-4 agonist from IDRI) gave the highest IgG antibody titer compared to other groups. Subsequent
<italic>in vivo</italic>
challenge experiments confirmed that >95% protection can be achieved when AL007 or AL019 was used as the adjuvant. However, when Imject® Alum or alhydrogel was used as the adjuvant only 76% and 72% protection respectively could be achieved. These results show that AL007 or AL019 (IDRI) is an excellent choice of adjuvant for the r
<italic>Bm</italic>
HATαc vaccine against
<italic>B. malayi</italic>
L3 in mice.</p>
</abstract>
<kwd-group>
<kwd>TLR-4 agonist</kwd>
<kwd>vaccine</kwd>
<kwd>Adjuvant</kwd>
<kwd>lymphatic filariasis</kwd>
<kwd>Alum</kwd>
<kwd>ADCC</kwd>
<kwd>
<italic>Brugia malayi</italic>
</kwd>
</kwd-group>
<funding-group>
<award-group>
<funding-source country="United States">National Institute of Allergy and Infectious Diseases Extramural Activities : NIAID</funding-source>
<award-id>R56 AI064745 || AI</award-id>
</award-group>
<award-group>
<funding-source country="United States">National Institute of Allergy and Infectious Diseases Extramural Activities : NIAID</funding-source>
<award-id>R01 AI064745 || AI</award-id>
</award-group>
</funding-group>
</article-meta>
</front>
</pmc>
<affiliations>
<list></list>
<tree>
<noCountry>
<name sortKey="Dakshinamoorthy, Gajalakshmi" sort="Dakshinamoorthy, Gajalakshmi" uniqKey="Dakshinamoorthy G" first="Gajalakshmi" last="Dakshinamoorthy">Gajalakshmi Dakshinamoorthy</name>
<name sortKey="Kalyanasundaram, Ramaswamy" sort="Kalyanasundaram, Ramaswamy" uniqKey="Kalyanasundaram R" first="Ramaswamy" last="Kalyanasundaram">Ramaswamy Kalyanasundaram</name>
</noCountry>
</tree>
</affiliations>
</record>

Pour manipuler ce document sous Unix (Dilib)

EXPLOR_STEP=$WICRI_ROOT/Wicri/Sante/explor/LymphedemaV1/Data/Pmc/Checkpoint
HfdSelect -h $EXPLOR_STEP/biblio.hfd -nk 002347 | SxmlIndent | more

Ou

HfdSelect -h $EXPLOR_AREA/Data/Pmc/Checkpoint/biblio.hfd -nk 002347 | SxmlIndent | more

Pour mettre un lien sur cette page dans le réseau Wicri

{{Explor lien
   |wiki=    Wicri/Sante
   |area=    LymphedemaV1
   |flux=    Pmc
   |étape=   Checkpoint
   |type=    RBID
   |clé=     PMC:3866973
   |texte=   Evaluating the efficacy of rBmHATαc as a multivalent vaccine against lymphatic filariasis in experimental animals and optimizing the adjuvant formulation
}}

Pour générer des pages wiki

HfdIndexSelect -h $EXPLOR_AREA/Data/Pmc/Checkpoint/RBID.i   -Sk "pubmed:24211167" \
       | HfdSelect -Kh $EXPLOR_AREA/Data/Pmc/Checkpoint/biblio.hfd   \
       | NlmPubMed2Wicri -a LymphedemaV1 

Wicri

This area was generated with Dilib version V0.6.31.
Data generation: Sat Nov 4 17:40:35 2017. Site generation: Tue Feb 13 16:42:16 2024